A new drug made by Eli Lilly and Co., called tirzepatide, is poised to become the most potent obesity drug on the market, promising users losses of more than...
Researchers have long looked for medications that can help people lose weight, mostly with disappointing and, in some cases, dangerous results. In recent years, however, drugs designed to help people with type 2 diabetes control their blood sugar levels have had the added effect of paring pounds.
Already approved under the brand name Mounjaro to treat type 2 diabetes, tirzepatide is being considered for fast-track approval as a weight-loss drug based on the results of key trials, with the latest announced on Thursday. The drugs that have drawn the most attention have been a class of medications that activate a hormone known as GLP-1. They include Ozempic and Wegovy, which are two versions of the same medication, semaglutide.
The obesity drugs lower blood sugar and slow down digestion, so people feel full longer. They also affect signals in the brain linked to feelings of fullness and satisfaction, tamping down appetite, food-related thoughts and cravings.In a trial, adults who took Wegovy saw a weight loss of nearly 35 pounds, or about 15% of their body weight. Adolescents lost about 16% of their body weight.
The drugs appear effective for chronic weight management over many months. In addition to weight loss, they also reduce health problems associated with obesity, such as high blood sugar and markers of heart and metabolic disease. Many people find it difficult to lose weight because of the body’s biological reactions to eating less, he said. There are several hormones that respond to reduced calorie intake by ramping up hunger to maintain body mass.The most common side effects are short-lived gastrointestinal issues such as nausea, vomiting, constipation, diarrhea and stomach pain.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Eli Lilly stock up premarket as company’s Q1 revenue beats and it raises guidanceEli Lilly & Co. shares rose 2% premarket Thursday, after the company posted first-quarter earnings showing a revenue beat and raised its full-year guidance....
Leer más »
People with diabetes lost up to 34 pounds taking Eli Lilly drug, company saysAn Eli Lilly drug helped obese patients with Type 2 diabetes lose 15% of their body weight, or about 34 pounds, on average, in a late-stage clinical trial, the drugmaker says.
Leer más »
Eli Lilly raises annual profit forecast on strength of diabetes drugEli Lilly and Co on Thursday raised its annual revenue and profit forecasts after topping first-quarter sales estimates on demand for its closely watched diabetes drug Mounjaro, ahead of a decision on its use as a treatment for obesity.
Leer más »
Eli Lilly says obesity drug tirzepatide resulted in weight loss of up to 34 poundsEli Lilly plans to complete its application for FDA approval of tirzepatide in the coming weeks and expects regulatory action as early as later this year.
Leer más »
Breakingviews - Eli Lilly races rising obesity expectationsThe race is on between Mounjaro’s growth and investors’ burgeoning hopes. The drug made by Eli Lilly , which was approved in May to treat diabetes, reaped an astonishing $569 million of revenue in the first quarter less than a year after it was approved for sale. The results encouraged Lilly to raise its annual profit guidance by 3.5%. Investors are counting on that growth becoming exponential.
Leer más »
Powerful new obesity drug from Eli Lilly and Co. poised to upend weight loss careAs a growing number of overweight Americans clamor for Ozempic and Wegovy — drugs touted by celebrities and on TikTok to pare pounds — an even more powerful obesity medicine is poised to upend treatment.
Leer más »